Solanezumab Doesn't Affect Cognitive Decline in Alzheimer's

Share this content:
Solanezumab Doesn't Affect Cognitive Decline in Alzheimer's
Solanezumab Doesn't Affect Cognitive Decline in Alzheimer's

FRIDAY, Jan. 26, 2018 (HealthDay News) -- For patients with mild Alzheimer's disease, solanezumab administered every four weeks does not alter cognitive decline, according to a study published in the Jan. 25 issue of the New England Journal of Medicine.

Lawrence S. Honig, M.D., Ph.D., from Columbia University Medical Center in New York City, and colleagues conducted a double-blind, placebo-controlled trial involving patients with mild dementia due to Alzheimer's disease. A total of 2,129 patients were enrolled and randomized to receive solanezumab (400 mg; 1,057 patients) or placebo (1,072 patients) intravenously every four weeks for 76 weeks.

The researchers found that the mean change from baseline in the score on the 14-item cognitive subscale of the Alzheimer's Disease Assessment Scale score was 6.65 and 7.44 in the solanezumab and placebo groups, respectively, with no significant difference between the groups at week 80 (difference, −0.8; 95 percent confidence interval, −1.73 to 0.14; P = 0.1). The change from baseline in the Mini-Mental State Examination score was −3.17 and −3.66 in the solanezumab and placebo groups, respectively.

"Solanezumab at a dose of 400 mg administered every four weeks in patients with mild Alzheimer's disease did not significantly affect cognitive decline," the authors write.

Several authors disclosed financial ties to pharmaceutical companies, including Eli Lilly, which funded the study.

Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

WHO: Congo Ebola Outbreak Not a Global Emergency

WHO: Congo Ebola Outbreak Not a Global Emergency

There have been 181 confirmed cases, including 104 deaths, so far in the outbreak

Sharp Drop in U.S. Life Expectancy Rankings by 2040

Sharp Drop in U.S. Life Expectancy Rankings by ...

U.S. expected to fall from 43rd in 2016 to 64th by 2040, with an average life expectancy of 79.8

Mortality Due to Suicide, Alcohol, Accidents Up in Diabetes

Mortality Due to Suicide, Alcohol, Accidents Up in ...

Patients with diabetes have higher mortality in nearly all end points, especially for insulin-treated

is free, fast, and customized just for you!




Already a member?

Sign In Now »